US Patent Issued to Deka Biosciences on Feb. 17 for "Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof" (Maryland Inventor)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,849, issued on Feb. 17, was assigned to Deka Biosciences Inc. (Germantown, Md.).

"Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof" was invented by John Mumm (Germantown, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides for various methods including a method of reducing the severity of bispecific T cell engager (BiTE) or chimeric antigen receptor T cell (CAR-T) induced cytokine release syndrome (CRS) comprising administering to a patient in need thereof an amount of a composition comprising an interleuki...